{"id":6848,"date":"2025-05-30T11:24:54","date_gmt":"2025-05-30T17:24:54","guid":{"rendered":"https:\/\/www.crpa-acrp-bulletin.ca\/?p=6848"},"modified":"2025-05-30T11:24:54","modified_gmt":"2025-05-30T17:24:54","slug":"une-tradition-de-decouverte-lelargissement-des-horizons-de-recherche-de-triumf","status":"publish","type":"post","link":"https:\/\/www.crpa-acrp-bulletin.ca\/fr\/2025\/05\/30\/une-tradition-de-decouverte-lelargissement-des-horizons-de-recherche-de-triumf\/","title":{"rendered":"Une tradition de d\u00e9couverte : l’\u00e9largissement des horizons de recherche de TRIUMF"},"content":{"rendered":"

\"\"<\/h2>\n

<\/a><\/p>\n

TRIUMF: A Brief History<\/h2>\n

TRIUMF, Canada\u2019s national particle accelerator centre, has been pushing the envelope of subatomic physics research and innovation for over 50 years. It was founded in 1968 in Vancouver, BC, as a joint venture between the physics departments of three local universities: University of British Columbia, University of Victoria, and Simon Fraser University.<\/p>\n

The goal was to wield short-lived subatomic particles called mesons\u2014produced using a then newly constructed 520 MeV cyclotron (the largest in the world!)\u2014to advance our understanding of the fundamental building blocks of matter.<\/p>\n

Since then, the \u201cTRI-University Meson Facility\u201d has expanded both its university member base (which today includes 21 university partners from Victoria to Halifax) and its research scope (moving beyond fundamental physics research into nuclear astrophysics, life sciences and radioisotope innovation, molecular and materials science, engineering, and beyond), making it a key player in both national and international scientific communities. It is Canada\u2019s largest single investment in major research infrastructure, and it convenes \/ channels over 80% of all subatomic physics research in Canada.<\/p>\n

In its early years, TRIUMF focused primarily on nuclear and particle physics, particularly in areas related to the study of subatomic particles, such as mesons, kaons, protons, and neutrons. The lab\u2019s flagship particle accelerator, the world\u2019s-largest 520 MeV cyclotron, enabled researchers to probe the mysteries of atomic nuclei and investigate a variety of different phenomena in particle physics and materials science.<\/p>\n

As time has passed, TRIUMF\u2019s science program has evolved to encompass a broader range of research disciplines, reflecting the lab\u2019s increasing versatility and capacity to respond to new scientific challenges.<\/p>\n

Today, TRIUMF\u2019s research program spans a broad variety of work that includes particle physics, nuclear physics and nuclear astrophysics, fundamental symmetries and exotic decays, medical isotopes, and materials science. The lab also serves as Canada\u2019s portal to international \u201cBig Science,\u201d designing and building detectors for major global science initiatives like the ATLAS experiment at CERN and the Hyper-K experiment in Japan.<\/p>\n

One of TRIUMF\u2019s most notable expansions has been into the production of medical isotopes, which are crucial in the diagnosis and treatment of various diseases, including cancer, Alzheimer\u2019s, and other neurodegenerative diseases. TRIUMF\u2019s work includes research into characterizing novel radioisotopes and investigating new and potentially life-saving isotopes, as well as ramping up on-site production of the critically needed and well-established isotopes used for PET and SPECT scanning.<\/p>\n

Nearly 40 years ago, TRIUMF also began its first major industrial partnership, with Atomic Energy Canada Limited, which saw TRIUMF begin to produce diagnostic radioisotopes using its on-site accelerators. Today, the lab produces nearly 2 million patient doses per year.<\/p>\n